Indaptus Therapeutics Inc Stock Price, News & Analysis

Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey Meckler will present at the Maxim Group 2022 Virtual Growth Conference on March 28, 2022, at 9:00 a.m. ET. The presentation will be pre-recorded, and an audio webcast will be accessible for 90 days via Indaptus' website. The company focuses on immunotherapy solutions leveraging patented technology involving non-pathogenic bacteria to activate immune responses for anti-tumor and anti-viral applications. Indaptus has successfully manufactured its lead candidate, Decoy20, and has completed various IND enabling studies.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) reported its financial results for Q4 and the year ending December 31, 2021. R&D expenses rose 150% to $1 million for Q4, while total R&D costs decreased 4% to $2.5 million for the year. G&A expenses surged 475% to $2.3 million in Q4, totaling $5.2 million annually, mainly due to payroll and public company costs post-Decoy merger. The company recorded a loss per share of $1.89 and had $39.1 million in cash as of year-end. Net cash used in operating activities ballooned to $11.3 million. Financing activities generated $48.3 million in 2021.

Indaptus Therapeutics (Nasdaq: INDP) announces that Dr. Michael J. Newman will present at the 3rd Annual STING & TLR-Targeting Therapies Summit from March 22-24, 2022. The presentation titled “Eradication of Established Tumors with Induction of Innate & Adaptive Immunological Memory” is scheduled for March 24 at 11:30 AM ET. Dr. Newman will also participate in a panel discussion on the best modalities for PRR-pathway targeting later that day at 1:30 PM ET. Indaptus focuses on innovative immunotherapy solutions with a patented technology that combines non-pathogenic bacteria to enhance immune response.

Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey Meckler will present at the 34th Annual ROTH Conference on March 14-15, 2022. An audio webcast of this presentation is available here and on the company's website, where it will be archived for 90 days. Indaptus focuses on immunotherapy, employing a multi-targeted approach for anti-tumor and anti-viral responses.

Indaptus Therapeutics (Nasdaq: INDP) announced CEO Jeffrey Meckler will present at the H.C. Wainwright BioConnect 2022 Virtual Conference on January 10 at 7:00 a.m. ET. The presentation will be pre-recorded and available via an audio webcast on the company's website, archived for approximately 90 days. Indaptus focuses on immunotherapy, using patented technology to activate immune responses for anti-tumor and anti-viral treatments. Their lead candidate, Decoy20, has undergone successful GMP manufacturing and is progressing with IND enabling studies.

Indaptus Therapeutics (Nasdaq: INDP) announces Dr. Boyan Litchev as the new Chief Medical Officer, effective January 31, 2022. Dr. Litchev brings over 20 years of experience in clinical oncology and medical leadership, having previously served at Shoreline Biosciences and Poseida Therapeutics. He will lead clinical strategies and the upcoming Phase 1 study of Decoy20, anticipated in 2022. The appointment is seen as a pivotal move towards advancing Indaptus's innovative immunotherapy platform aimed at treating various diseases through enhanced immune activation.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) announces the appointment of Mark Gilbert, M.D., formerly Chief Medical Officer at Juno Therapeutics, to its Board of Directors, effective immediately. He replaces Hoonmo Lee, who has stepped down. Dr. Gilbert brings significant oncology expertise, having led pioneering CAR-T cell therapy developments. CEO Jeffrey Meckler expressed confidence that Dr. Gilbert’s experience will enhance the company’s immunotherapy pipeline. Indaptus utilizes patented technology aimed at activating both innate and adaptive immunity for cancer treatment.

Indaptus Therapeutics (Nasdaq: INDP) reported financial results for Q3 2021, highlighting a transformative quarter with the merger with Decoy Biosystems and a $30 million private placement. Research and development expenses decreased by 48% year-over-year to approximately $0.7 million, while general and administrative expenses surged by 1,260% to about $2.7 million. The company reported a loss per share of $0.81, slightly higher than $0.79 for Q3 2020. As of September 30, 2021, cash and cash equivalents stood at approximately $41.9 million, up from $1.6 million at the end of 2020.

Indaptus Therapeutics announced a significant advancement as the United States Patent and Trademark Office has allowed claims for their platform technology aimed at treating HBV and HIV infections. The patent, titled 'Methods of Treatment of Infections Using Bacteria,' grants broad protection for their innovative approach. This development validates Indaptus' strategy to activate immune responses against viral infections. The company aims to further explore partnerships for technology development, following promising pre-clinical results demonstrating enhanced therapeutic efficacy.